FDA orphan designation for zenocutuzumab‑zbco targets NRG1 fusion–positive advanced cholangiocarcinoma, a small molecular subset within an aggressive malignancy with <15% five-year survival. Orphan ...
On February 3, 2026, President Trump signed H.R.7148, the Consolidated Appropriations Act, 2026, into law. Section 6703 of the Act, ...
The large molecule drug substance CDMO market is projected to grow at a CAGR of approximately 9% over the forecast period. This growth is primarily driven by the rising demand for biologics and ...
With a shared purpose, we can realize the true promise of CRISPR and improve healthcare, providing hope to more patients with ...
Marcio Temtem, vice president, Strategic Business Management, Hovione, addresses molecule complexity, speed, and ...
Autophagy a self-eating process where the body’s cells recycle their own damaged components to maintain health Our experts ...
Kor, opens new tab, a U.S.-based nutraceutical company focused on science-informed longevity formulations for vitality and ...
STAAR study demonstrated positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which U.S. Food and Drug Administration (FDA) ...
Introducing cell therapy--grade cryopreservation and hypothermic storage solutions designed for consistency, quality, and performance across cell therapy workflows ST. PETERSBURG, Fla., Feb. 6, 2026 ...
Message from CEO IBT's plan to apply for marketing approval in the US through a so-called accelerated application remains unchanged. The development program for IBP-9414 is "Breakthrough Designated," ...
AI promised to speed up drug discovery, but the real bottleneck is in clinical trials. This startup is using AI to accelerate ...
Congress enacted the fiscal year 2026 Labor, Health and Human Services, Education, and Related Agencies (LHHS) appropriations bill, providing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results